/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

NEXIMMUNE INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$3.45 0.7013(70.13%) NEXI at 04 Dec 2025 04:39 PM Biotechnology
Lowest Today 2.3051
Highest Today 7.0499
Today’s Open 2.31
Prev. Close 2.31
52 Week High 21.00
52 Week Low 1.25
Day’s Range: Low 2.3051 High 7.0499
52-Week Range: Low 1.25 High 21.00
1 day return -
1 Week return -
1 month return -
3 month return -
6 month return -
1 year return -
3 year return -61.04
5 year return -
10 year return -

Institutional Holdings

Sabby Management LLC 4.37

Slate Path Capital LP 2.70

EPIQ Capital Group, LLC 1.14

PNC Financial Services Group Inc 0.92

Vanguard Group Inc 0.88

Vanguard Institutional Extnd Mkt Idx Tr 0.88

Raymond James & Associates 0.79

Comerica Bank 0.24

Fidelity Extended Market Index 0.23

Tower Research Capital LLC 0.12

DFA US Small Cap I 0.08

Fidelity Nasdaq Composite Index 0.03

Fidelity Series Total Market Index 0.02

Fidelity Total Market Index 0.02

NT Ext Equity Mkt Idx Fd - NL 0.02

Northern Trust Extended Eq Market Idx 0.02

NT Ext Equity Mkt Idx Fd - L 0.02

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.01

Royal Bank of Canada 0.01

SSgA U.S. Extended Market Index Class I 0.01

State St US Extended Mkt Indx NL Cl C 0.01

Spartan Total Market Index Pool E 0.01

BNP Paribas Arbitrage, SA 0.00

Spartan Extended Market Index Pool E 0.00

SSgA U.S. Total Market Index Strategy 0.00

Northern Trust Wilshire 5000 0.00

NT US Market Cap Idx Fd - L 0.00

BlackRock Extended Mkt Composite 0.00

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

BNYM Mellon SL Market Completion UC1 0.00

Wells Fargo & Co 0.00

UBS Group AG 0.00

Adage Capital Partners Gp LLC 0.00

BlackRock Inc 0.00

Caprock Group Inc 0.00

Morgan Stanley - Brokerage Accounts 0.00

Market Status

Strong Buy: 0

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 3.17 M

PB Ratio 1.0514

PE Ratio 0.0

Enterprise Value -1.29 M

Total Assets 8.59 M

Volume 34525137

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-43878793 -43.9M, FY22:514183801 514.2M, FY21:-51745427 -51.7M, FY20:-31638668 -31.6M, FY19:-20299931 -20.3M

Quarterly Revenue Q1/2024:2120558 2.1M, Q4/2023:0 0.0M, Q3/2023:0 0.0M, Q2/2023:0 0.0M, Q1/2023:0 0.0M

Quarterly Profit Q1/2024:1892049 1.9M, Q4/2023:null 0.0M, Q3/2023:null 0.0M, Q2/2023:null 0.0M, Q1/2023:null 0.0M

Quarterly Net worth Q1/2024:-5358625 -5.4M, Q4/2023:-5358625 -5.4M, Q3/2023:-9854187 -9.9M, Q2/2023:-7566504 -7.6M, Q1/2023:250766923 250.8M

Fund house & investment objective

Company Information NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

Organisation Biotechnology

Employees 6

Industry Biotechnology

CEO Ms. Kristi Jones R.Ph.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow